EMD 521873 in Advanced Solid Tumors, MTD Finding

NCT01032681 | Completed Phase 1

• 1 other identifier: EMR62235_001
• Study Type: interventional
• Target: 66
• Locations: 2 countries
• Sites: 5

Brief Summary

Primary trial objective in this three arm trial is to assess the safety and tolerability of EMD 521873, and to determine whether the maximum tolerated dose (MTD) is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose cyclophosphamide (CPA) in patients with metastatic or locally advanced solid tumors or B-cell non-Hodgkin lymphoma. Secondary objectives are to evaluate pharmacokinetic, immunogenicity, overall and best clinical response, changes in tumor marker levels, survival and biological/immune responses to EMD 521873. A total of 78 patients are planned. Patients will remain on the dose throughout the trial. It is intended to administer 3 cycles (21 d each, or until progression or a xxx line therapy becomes necessary.

Conditions

Non-Hodgkin Lymphoma

Keywords

Solid tumor; B-Cell Non-Hodgkin Lymphoma; Immunocytokine; interleukin-2; immunotherapy; Metastatic or Locally Advanced Solid Tumors or B-Cell Non-Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (2)

• Assess the safety and tolerability of EMD 521873

  First administration of any dose of EMD521873 until last administration plus 30 days.

• To determine whether the MTD is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose CPA in patients with metastatic or locally advanced solid tumors or B-cell non-Hodgkin lymphoma

  Incidence of DLTs occurring during the first cycle of administration of any dose of EMD 521873 given alone on 3 times per cycle (group 1) or with fixed low-dose CPA plus EMD 521873 (group 2) or of EMD 521873 given alone on once per cycle (group 3).

Secondary Outcomes (5)

• Characterize the PK profile of EMD 521873 alone or in combination with fixed lowdose CPA

  Cycle 1-3 of EMD 521873 treatment

• Evaluate the immunogenicity of EMD 521873 alone or in combination with CPA measured by the induction of o Specific antibodies against the genetically modified IL-2 o Fc-IL2-specific antibodies o Anti-idiotype antibodies

  Every EMD 521873 treatment cycle

• Collect evidence of best overall response, changes in serum tumor marker levels and best clinical response after treatment with EMD 521873 alone or in combination with CPA

  Every second EMD 521873 treatment cycle

• Evaluate survival

  Until 1 year after the last patient received his last dose of EMD 521873

• Evaluate biological responses to EMD 521873 alone or in combination with CPA as measured by o Absolute cell numbers and ratios of lymphocyte subsets in defined combinations o Change in serum level of sIL2R and neopterin

  Cycle 1-3 of EMD 521873 treatment

Study Arms (3)

Group 1

EXPERIMENTAL

Dose escalation of EMD 521873 monotheraphy 3 doses per cycle

Biological: EMD 521873

Group 2

EXPERIMENTAL

Low dose CPA + Dose escalation of EMD 521873 three doses per cycle

Biological: EMD 521873

Group 3

EXPERIMENTAL

Dose escalation of EMD 521873 monotheraphy 1 dose per cycle

Biological: EMD 521873

Interventions

EMD 521873 BIOLOGICAL

Dose escalation steps: Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg) Disease control and decision of continuation in patient who benefit from the treatment: Every second cycle

Group 1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed written informed consent
• Male or female, aged ≥ 18 years, inpatient for treatment phase of cycle 1 and 2, outpatient treatment possible for subsequent cycles
• Histologically or cytologically proven metastatic or locally advanced solid tumors (epithelial or mesenchymal cancers) or B-cell non-Hodgkin lymphoma for which no standard therapy exists or after failure of standard therapy
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at study entry and an estimated life expectancy of at least 3 months
• Adequate hematological function defined by WBC count ≥ 3 x 109/L with absolute neutrophil count (ANC) ≥ 1.5 x 109/L and lymphocyte count ≥ 0.5 x 109/L; platelet count ≥100 x 109/L; hemoglobin ≥9 g/dL ( If the laboratory values for hemoglobin are outside the required entry level at Screening, a patient may receive a transfusion of RBC. A stable hemoglobin level of ≥9 mg/dL for at least 7 days must be achieved prior to receiving the first dose of study medication.)
• Adequate hepatic function defined by a total bilirubin level ≤ 1.5 times the upper limit of normal (ULN) and aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT) levels ≤ 2.5 x ULN or, for patients with documented metastatic disease to the liver, AST and ALT levels ≤ 5 x ULN
• No history of acute or chronic kidney disease and adequate renal function defined by an estimated creatinine clearance above 50 mL/min determined by 24-hour urine sampling or by the Cockcroft-Gault formula
• Effective contraception for both male and female subjects if the risk of conception exists

You may not qualify if:

• Prior IL-2 therapy within the last 6 months
• Requirement for concurrent anticancer treatment (chemotherapy, radiotherapy, immune therapy, cytokine therapy except erythropoietin) or for concurrent systemic therapy with steroids or other immunosuppressive agents. Short-term administration of steroids (i.e. for allergic reactions) is allowed.
• Radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before the start of treatment in this study
• Acquired immune defects such as human immunodeficiency virus (HIV)
• Systemic autoimmune disease (e.g. lupus erythematodes, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma)
• Organ transplant recipients
• History of or active inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)
• Chronic viral infections (e.g. hepatitis B virus \[HBV\], hepatitis C virus \[HCV\])
• Uncontrolled hypertension (systolic \>180 mmHg, diastolic \>100 mmHg)
• Known hypersensitivity reactions to any of the compounds of the study medication
• Confirmed or clinically suspected brain metastases
• Pregnancy (absence to be confirmed by beta-human chorionic gonadotropin \[β-HCG\] test) or lactation period
• Clinically significant (i.e. active) cardiovascular disease: Cerebral vascular accident /stroke (\< 6 months prior to enrolment), myocardial infarction (\< 6 months prior to enrolment), unstable angina, congestive heart failure or serious cardiac arrhythmia requiring medication.
• Pulmonary disease which, in the opinion of the investigator, might impair the patient's respiratory tolerance to moderate pulmonary fluid overload (e.g. interstitial lung disease, severe chronic obstructive pulmonary disease)
• All conditions which are associated with significant necroses of non tumor-bearing tissues like e.g. esophageal or gastroduodenal ulcers (\< 6 months prior to enrolment), organ infarctions (\< 6 months prior to enrolment) or active ischemic bowel disease

Sponsors & Collaborators

• Merck KGaA, Darmstadt, Germany: lead

Study Sites (5)

Universitäts-Klinikum Mainz III.Medizinische Klinik

Mainz, Germany

Location

Medizinische Klinik Universitätsklinikum Mannheim Medizinische Fakultät Mannheim

Mannheim, Germany

Location

Istituto Oncologico della Svizzera Italiana Ospedale Regionale Bellinzona e Valli (IOSI)

Bellinzona, Switzerland

Location

University of Lausanne Hospitals (CHUV) and Hospitals of Riveria-Chablais

Lausanne, Switzerland

Location

Kantonsspital St. Gallen

Sankt Gallen, Switzerland

Location

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Neoplasm Metastasis

Interventions

EMD 521873

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Jens-Peter Marschner, MD

  Merck KGaA, Darmstadt, Germany

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 11, 2009
• First Posted: December 15, 2009
• Study Start: December 1, 2006
• Primary Completion: February 1, 2011
• Study Completion: January 1, 2012
• Last Updated: July 31, 2014

Record last verified: 2012-10

Locations

CH (3); DE (2)